162 related articles for article (PubMed ID: 23062739)
1. A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles.
Blokhina EA; Kuprianov VV; Stepanova LA; Tsybalova LM; Kiselev OI; Ravin NV; Skryabin KG
Virology; 2013 Jan; 435(2):293-300. PubMed ID: 23062739
[TBL] [Abstract][Full Text] [Related]
2. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
4. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.
Ravin NV; Kotlyarov RY; Mardanova ES; Kuprianov VV; Migunov AI; Stepanova LA; Tsybalova LM; Kiselev OI; Skryabin KG
Biochemistry (Mosc); 2012 Jan; 77(1):33-40. PubMed ID: 22339631
[TBL] [Abstract][Full Text] [Related]
5. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
[TBL] [Abstract][Full Text] [Related]
6. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
Neirynck S; Deroo T; Saelens X; Vanlandschoot P; Jou WM; Fiers W
Nat Med; 1999 Oct; 5(10):1157-63. PubMed ID: 10502819
[TBL] [Abstract][Full Text] [Related]
7. A "universal" human influenza A vaccine.
Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
[TBL] [Abstract][Full Text] [Related]
8. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
[TBL] [Abstract][Full Text] [Related]
9. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.
Sominskaya I; Skrastina D; Dislers A; Vasiljev D; Mihailova M; Ose V; Dreilina D; Pumpens P
Clin Vaccine Immunol; 2010 Jun; 17(6):1027-33. PubMed ID: 20410327
[TBL] [Abstract][Full Text] [Related]
10. Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles.
Sun C; Ding FX; Wang F; He XW; He Y; Li ZS; Sun SH
Microbiol Immunol; 2009 Jun; 53(6):340-8. PubMed ID: 19493202
[TBL] [Abstract][Full Text] [Related]
11. Behavior of a short preS1 epitope on the surface of hepatitis B core particles.
Borisova G; Borschukova O; Skrastina D; Dislers A; Ose V; Pumpens P; Grens E
Biol Chem; 1999 Mar; 380(3):315-24. PubMed ID: 10223334
[TBL] [Abstract][Full Text] [Related]
12. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
13. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
14. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B core-based virus-like particles to present heterologous epitopes.
Roose K; De Baets S; Schepens B; Saelens X
Expert Rev Vaccines; 2013 Feb; 12(2):183-98. PubMed ID: 23414409
[TBL] [Abstract][Full Text] [Related]
16. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus.
Zhang YL; Guo YJ; Wang KY; Lu K; Li K; Zhu Y; Sun SH
Scand J Immunol; 2007 Apr; 65(4):320-8. PubMed ID: 17386022
[TBL] [Abstract][Full Text] [Related]
17. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
[TBL] [Abstract][Full Text] [Related]
18. Universal influenza A vaccine: optimization of M2-based constructs.
De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
[TBL] [Abstract][Full Text] [Related]
19. Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.
Isaguliants MG; Kadoshnikov YP; Kalinina TI; Smirnov VD; Wahren B
Biochemistry (Mosc); 1998 May; 63(5):551-8. PubMed ID: 9632891
[TBL] [Abstract][Full Text] [Related]
20. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
Zhou C; Zhou L; Chen YH
Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
